Terazosin Hydrochloride Anhydrous

Product NDC: 51079-937
11-digit product format: 510790937
Labeler code: 51079
Product ID: 51079-937_9af1cfd2-0dea-a218-e053-2995a90a4efd
Type: HUMAN PRESCRIPTION DRUG
Nonproprietary name: terazosin hydrochloride anhydrous
Dosage form: CAPSULE
Route: ORAL
Labeler: Mylan Institutional Inc.
Application: ANDA075140
Marketing category: ANDA
Marketing start: 2000-04-01
Marketing end: 2021-01-31
Substance: TERAZOSIN HYDROCHLORIDE ANHYDROUS
Active strength: 2 mg/1
Pharmacologic classes: Adrenergic alpha-Antagonists [MoA],alpha-Adrenergic Blocker [EPC]
NDC exclude flag: No
Listing certified through: 0000-00-00
Current FDA listing: Historical FDA.report record

NDC auxiliary status#

These records are reproduced from FDA’s unfinished, excluded, and compounder listings. They describe what appeared in the source files; a missing record does not establish a regulatory status. View all current auxiliary records, including entries without an NDC. · View the auxiliary file history.

Current NDC status page 1 of 1 · 2 matching rows.

Dataset, Scope, Product NDC table
Dataset	Scope	Product NDC	Package NDC	Code	Status	Reporting period	Source date
excluded product	product	51079-937		D	Discontinued by firm		2026-10-05
excluded package	package	51079-937	51079-937-20	D	Discontinued by firm		2026-10-05

Observed NDC auxiliary status history#

This history shows the information present in each captured FDA auxiliary file. It is not a continuous regulatory timeline, and a missing record does not establish a status.

Historic NDC status page 1 of 1 · 24 matching rows.

View current auxiliary records. · View the auxiliary file history.

Captured / source date, Dataset, Scope table
Captured / source date	Dataset	Scope	Package NDC	Snapshot	Source SHA-256
2025-12-14 17:58 UTC · source 2025-12-05	excluded product	product		`d630ba8d3edf…`	`732f749b63fb…`
2025-12-14 17:58 UTC · source 2025-12-05	excluded package	package	51079-937-20	`d630ba8d3edf…`	`732f749b63fb…`
2025-08-27 00:01 UTC · source 2025-08-26	excluded product	product		`f5e01cc5f278…`	`a2eaf40c39c3…`
2025-08-27 00:01 UTC · source 2025-08-26	excluded package	package	51079-937-20	`f5e01cc5f278…`	`a2eaf40c39c3…`
2025-04-01 02:39 UTC · source 2025-03-31	excluded product	product		`2ef7874e63bc…`	`57b86245f4fa…`
2025-04-01 02:39 UTC · source 2025-03-31	excluded package	package	51079-937-20	`2ef7874e63bc…`	`57b86245f4fa…`
2025-03-28 20:22 UTC · source 2025-03-28	excluded product	product		`a1b67e2a42f9…`	`c4cf2c586c0d…`
2025-03-28 20:22 UTC · source 2025-03-28	excluded package	package	51079-937-20	`a1b67e2a42f9…`	`c4cf2c586c0d…`
2025-03-22 03:12 UTC · source 2025-03-21	excluded product	product		`cfe11265f3b6…`	`090c488252e2…`
2025-03-22 03:12 UTC · source 2025-03-21	excluded package	package	51079-937-20	`cfe11265f3b6…`	`090c488252e2…`
2025-03-10 12:48 UTC · source 2025-03-10	excluded product	product		`cdf11ea48f46…`	`ba0047e9e063…`
2025-03-10 12:48 UTC · source 2025-03-10	excluded package	package	51079-937-20	`cdf11ea48f46…`	`ba0047e9e063…`
2025-02-02 03:52 UTC · source 2025-01-31	excluded product	product		`302b2466d912…`	`e7b80fea0513…`
2025-02-02 03:52 UTC · source 2025-01-31	excluded package	package	51079-937-20	`302b2466d912…`	`e7b80fea0513…`
2025-01-20 13:05 UTC · source 2025-01-20	excluded product	product		`ed331223b511…`	`672a5bd82f5f…`
2025-01-20 13:05 UTC · source 2025-01-20	excluded package	package	51079-937-20	`ed331223b511…`	`672a5bd82f5f…`
2025-01-11 03:41 UTC · source 2025-01-10	excluded product	product		`0efc9e666f02…`	`f202fb6c5f17…`
2025-01-11 03:41 UTC · source 2025-01-10	excluded package	package	51079-937-20	`0efc9e666f02…`	`f202fb6c5f17…`
2024-11-09 02:27 UTC · source 2024-11-08	excluded product	product		`ad56d346431e…`	`cc804d4bbf1e…`
2024-11-09 02:27 UTC · source 2024-11-08	excluded package	package	51079-937-20	`ad56d346431e…`	`cc804d4bbf1e…`
2024-10-04 04:10 UTC · source 2024-10-03	excluded product	product		`367a005e9d99…`	`383a685ebd0f…`
2024-10-04 04:10 UTC · source 2024-10-03	excluded package	package	51079-937-20	`367a005e9d99…`	`383a685ebd0f…`
2024-07-10 04:00 UTC · source 2024-07-09	excluded product	product		`557ba5c1ecfa…`	`9c80585c8c6e…`
2024-07-10 04:00 UTC · source 2024-07-09	excluded package	package	51079-937-20	`557ba5c1ecfa…`	`9c80585c8c6e…`

Source provenance: Browse the complete Orange Book source catalog · source snapshot 43.

Orange Book products#

Current product rows page 1 of 1 · 4 matching rows.

Application-product, Trade name, Ingredient table
Application-product	Trade name	Ingredient	Strength	Dosage form / route	Approval date
A075140-001	TERAZOSIN HYDROCHLORIDE	TERAZOSIN HYDROCHLORIDE	EQ 5MG BASE	CAPSULE / ORAL	2000-02-11
A075140-002	TERAZOSIN HYDROCHLORIDE	TERAZOSIN HYDROCHLORIDE	EQ 1MG BASE	CAPSULE / ORAL	2000-02-11
A075140-003	TERAZOSIN HYDROCHLORIDE	TERAZOSIN HYDROCHLORIDE	EQ 2MG BASE	CAPSULE / ORAL	2000-02-11
A075140-004	TERAZOSIN HYDROCHLORIDE	TERAZOSIN HYDROCHLORIDE	EQ 10MG BASE	CAPSULE / ORAL	2000-02-11

Observed Orange Book product history#

Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.

Product history page 1 of 5 · 172 observed states.

Captured, Edition, Application-product table
Captured	Edition	Application-product	Trade name	Strength	Dosage form / route	Approval date	Source SHA-256
2026-09-14 22:38:34	2026-08	A075140-001	TERAZOSIN HYDROCHLORIDE	EQ 5MG BASE	CAPSULE / ORAL	2000-02-11	`84e616aacf4f…`
2026-09-14 22:38:34	2026-08	A075140-002	TERAZOSIN HYDROCHLORIDE	EQ 1MG BASE	CAPSULE / ORAL	2000-02-11	`84e616aacf4f…`
2026-09-14 22:38:34	2026-08	A075140-003	TERAZOSIN HYDROCHLORIDE	EQ 2MG BASE	CAPSULE / ORAL	2000-02-11	`84e616aacf4f…`
2026-09-14 22:38:34	2026-08	A075140-004	TERAZOSIN HYDROCHLORIDE	EQ 10MG BASE	CAPSULE / ORAL	2000-02-11	`84e616aacf4f…`
2026-08-18 06:07:40	2026-07	A075140-001	TERAZOSIN HYDROCHLORIDE	EQ 5MG BASE	CAPSULE / ORAL	2000-02-11	`caaa826d4ba7…`
2026-08-18 06:07:40	2026-07	A075140-002	TERAZOSIN HYDROCHLORIDE	EQ 1MG BASE	CAPSULE / ORAL	2000-02-11	`caaa826d4ba7…`
2026-08-18 06:07:40	2026-07	A075140-003	TERAZOSIN HYDROCHLORIDE	EQ 2MG BASE	CAPSULE / ORAL	2000-02-11	`caaa826d4ba7…`
2026-08-18 06:07:40	2026-07	A075140-004	TERAZOSIN HYDROCHLORIDE	EQ 10MG BASE	CAPSULE / ORAL	2000-02-11	`caaa826d4ba7…`
2026-02-19 14:30 UTC	2026-02	A075140-001	TERAZOSIN HYDROCHLORIDE	EQ 5MG BASE	CAPSULE / ORAL	2000-02-11	`011fe1cb6892…`
2026-02-19 14:30 UTC	2026-02	A075140-002	TERAZOSIN HYDROCHLORIDE	EQ 1MG BASE	CAPSULE / ORAL	2000-02-11	`011fe1cb6892…`
2026-02-19 14:30 UTC	2026-02	A075140-003	TERAZOSIN HYDROCHLORIDE	EQ 2MG BASE	CAPSULE / ORAL	2000-02-11	`011fe1cb6892…`
2026-02-19 14:30 UTC	2026-02	A075140-004	TERAZOSIN HYDROCHLORIDE	EQ 10MG BASE	CAPSULE / ORAL	2000-02-11	`011fe1cb6892…`
2025-12-14 10:44 UTC · 2 captures of this ZIP	2025-12	A075140-001	TERAZOSIN HYDROCHLORIDE	EQ 5MG BASE	CAPSULE / ORAL	2000-02-11	`31067a03dcf5…`
2025-12-14 10:44 UTC · 2 captures of this ZIP	2025-12	A075140-002	TERAZOSIN HYDROCHLORIDE	EQ 1MG BASE	CAPSULE / ORAL	2000-02-11	`31067a03dcf5…`
2025-12-14 10:44 UTC · 2 captures of this ZIP	2025-12	A075140-003	TERAZOSIN HYDROCHLORIDE	EQ 2MG BASE	CAPSULE / ORAL	2000-02-11	`31067a03dcf5…`
2025-12-14 10:44 UTC · 2 captures of this ZIP	2025-12	A075140-004	TERAZOSIN HYDROCHLORIDE	EQ 10MG BASE	CAPSULE / ORAL	2000-02-11	`31067a03dcf5…`
2025-08-23 18:47 UTC	2025-08	A075140-001	TERAZOSIN HYDROCHLORIDE	EQ 5MG BASE	CAPSULE / ORAL	2000-02-11	`6a471c1ec25d…`
2025-08-23 18:47 UTC	2025-08	A075140-002	TERAZOSIN HYDROCHLORIDE	EQ 1MG BASE	CAPSULE / ORAL	2000-02-11	`6a471c1ec25d…`
2025-08-23 18:47 UTC	2025-08	A075140-003	TERAZOSIN HYDROCHLORIDE	EQ 2MG BASE	CAPSULE / ORAL	2000-02-11	`6a471c1ec25d…`
2025-08-23 18:47 UTC	2025-08	A075140-004	TERAZOSIN HYDROCHLORIDE	EQ 10MG BASE	CAPSULE / ORAL	2000-02-11	`6a471c1ec25d…`
2025-03-22 03:13 UTC · 3 captures of this ZIP	2025-03	A075140-001	TERAZOSIN HYDROCHLORIDE	EQ 5MG BASE	CAPSULE / ORAL	2000-02-11	`fd3edfee7708…`
2025-03-22 03:13 UTC · 3 captures of this ZIP	2025-03	A075140-002	TERAZOSIN HYDROCHLORIDE	EQ 1MG BASE	CAPSULE / ORAL	2000-02-11	`fd3edfee7708…`
2025-03-22 03:13 UTC · 3 captures of this ZIP	2025-03	A075140-003	TERAZOSIN HYDROCHLORIDE	EQ 2MG BASE	CAPSULE / ORAL	2000-02-11	`fd3edfee7708…`
2025-03-22 03:13 UTC · 3 captures of this ZIP	2025-03	A075140-004	TERAZOSIN HYDROCHLORIDE	EQ 10MG BASE	CAPSULE / ORAL	2000-02-11	`fd3edfee7708…`
2025-02-26 10:13 UTC · 3 captures of this ZIP	2025-02	A075140-001	TERAZOSIN HYDROCHLORIDE	EQ 5MG BASE	CAPSULE / ORAL	2000-02-11	`b8a1b40f171c…`
2025-02-26 10:13 UTC · 3 captures of this ZIP	2025-02	A075140-002	TERAZOSIN HYDROCHLORIDE	EQ 1MG BASE	CAPSULE / ORAL	2000-02-11	`b8a1b40f171c…`
2025-02-26 10:13 UTC · 3 captures of this ZIP	2025-02	A075140-003	TERAZOSIN HYDROCHLORIDE	EQ 2MG BASE	CAPSULE / ORAL	2000-02-11	`b8a1b40f171c…`
2025-02-26 10:13 UTC · 3 captures of this ZIP	2025-02	A075140-004	TERAZOSIN HYDROCHLORIDE	EQ 10MG BASE	CAPSULE / ORAL	2000-02-11	`b8a1b40f171c…`
2025-01-19 17:59 UTC · 7 captures of this ZIP	2025-01	A075140-001	TERAZOSIN HYDROCHLORIDE	EQ 5MG BASE	CAPSULE / ORAL	2000-02-11	`03ed91905a0d…`
2025-01-19 17:59 UTC · 7 captures of this ZIP	2025-01	A075140-002	TERAZOSIN HYDROCHLORIDE	EQ 1MG BASE	CAPSULE / ORAL	2000-02-11	`03ed91905a0d…`
2025-01-19 17:59 UTC · 7 captures of this ZIP	2025-01	A075140-003	TERAZOSIN HYDROCHLORIDE	EQ 2MG BASE	CAPSULE / ORAL	2000-02-11	`03ed91905a0d…`
2025-01-19 17:59 UTC · 7 captures of this ZIP	2025-01	A075140-004	TERAZOSIN HYDROCHLORIDE	EQ 10MG BASE	CAPSULE / ORAL	2000-02-11	`03ed91905a0d…`
2024-12-13 21:23 UTC · 2 captures of this ZIP	2024-12	A075140-001	TERAZOSIN HYDROCHLORIDE	EQ 5MG BASE	CAPSULE / ORAL	2000-02-11	`2680178bc6a6…`
2024-12-13 21:23 UTC · 2 captures of this ZIP	2024-12	A075140-002	TERAZOSIN HYDROCHLORIDE	EQ 1MG BASE	CAPSULE / ORAL	2000-02-11	`2680178bc6a6…`
2024-12-13 21:23 UTC · 2 captures of this ZIP	2024-12	A075140-003	TERAZOSIN HYDROCHLORIDE	EQ 2MG BASE	CAPSULE / ORAL	2000-02-11	`2680178bc6a6…`
2024-12-13 21:23 UTC · 2 captures of this ZIP	2024-12	A075140-004	TERAZOSIN HYDROCHLORIDE	EQ 10MG BASE	CAPSULE / ORAL	2000-02-11	`2680178bc6a6…`
2024-09-14 05:58 UTC · 2 captures of this ZIP	2024-09	A075140-001	TERAZOSIN HYDROCHLORIDE	EQ 5MG BASE	CAPSULE / ORAL	2000-02-11	`5bbf6a4d5a75…`
2024-09-14 05:58 UTC · 2 captures of this ZIP	2024-09	A075140-002	TERAZOSIN HYDROCHLORIDE	EQ 1MG BASE	CAPSULE / ORAL	2000-02-11	`5bbf6a4d5a75…`
2024-09-14 05:58 UTC · 2 captures of this ZIP	2024-09	A075140-003	TERAZOSIN HYDROCHLORIDE	EQ 2MG BASE	CAPSULE / ORAL	2000-02-11	`5bbf6a4d5a75…`
2024-09-14 05:58 UTC · 2 captures of this ZIP	2024-09	A075140-004	TERAZOSIN HYDROCHLORIDE	EQ 10MG BASE	CAPSULE / ORAL	2000-02-11	`5bbf6a4d5a75…`

Observed Orange Book normalized TE history#

Captured, Edition, Application-product table
Captured	Edition	Application-product	TE code	Order	Source SHA-256
2019-12-13 00:20 UTC	2019-12	A075140-001	AB	1	`74a2ff9319b5…`
2019-12-13 00:20 UTC	2019-12	A075140-002	AB	1	`74a2ff9319b5…`
2019-12-13 00:20 UTC	2019-12	A075140-003	AB	1	`74a2ff9319b5…`
2019-12-13 00:20 UTC	2019-12	A075140-004	AB	1	`74a2ff9319b5…`
2021-05-05 16:15 UTC · 3 captures of this ZIP	2021-05	A075140-001	AB	1	`87673890dc5c…`
2021-05-05 16:15 UTC · 3 captures of this ZIP	2021-05	A075140-002	AB	1	`87673890dc5c…`
2021-05-05 16:15 UTC · 3 captures of this ZIP	2021-05	A075140-003	AB	1	`87673890dc5c…`
2021-05-05 16:15 UTC · 3 captures of this ZIP	2021-05	A075140-004	AB	1	`87673890dc5c…`
2021-03-12 10:30 UTC	2021-03	A075140-001	AB	1	`5aa47cf7b7d7…`
2021-03-12 10:30 UTC	2021-03	A075140-002	AB	1	`5aa47cf7b7d7…`
2021-03-12 10:30 UTC	2021-03	A075140-003	AB	1	`5aa47cf7b7d7…`
2021-03-12 10:30 UTC	2021-03	A075140-004	AB	1	`5aa47cf7b7d7…`
2020-12-22 03:56 UTC	2020-12	A075140-001	AB	1	`8869cabd3fbd…`
2020-12-22 03:56 UTC	2020-12	A075140-002	AB	1	`8869cabd3fbd…`
2020-12-22 03:56 UTC	2020-12	A075140-003	AB	1	`8869cabd3fbd…`
2020-12-22 03:56 UTC	2020-12	A075140-004	AB	1	`8869cabd3fbd…`
2020-11-12 02:37 UTC	2020-11	A075140-001	AB	1	`c0c555d07b60…`
2020-11-12 02:37 UTC	2020-11	A075140-002	AB	1	`c0c555d07b60…`
2020-11-12 02:37 UTC	2020-11	A075140-003	AB	1	`c0c555d07b60…`
2020-11-12 02:37 UTC	2020-11	A075140-004	AB	1	`c0c555d07b60…`
2019-12-14 00:12 UTC	2019-12	A075140-001	AB	1	`3f01610625f2…`
2019-12-14 00:12 UTC	2019-12	A075140-002	AB	1	`3f01610625f2…`
2019-12-14 00:12 UTC	2019-12	A075140-003	AB	1	`3f01610625f2…`
2019-12-14 00:12 UTC	2019-12	A075140-004	AB	1	`3f01610625f2…`
2019-09-15 20:21 UTC	2019-09	A075140-001	AB	1	`b00525d2431f…`
2019-09-15 20:21 UTC	2019-09	A075140-002	AB	1	`b00525d2431f…`
2019-09-15 20:21 UTC	2019-09	A075140-003	AB	1	`b00525d2431f…`
2019-09-15 20:21 UTC	2019-09	A075140-004	AB	1	`b00525d2431f…`
2019-07-19 19:46 UTC	2019-07	A075140-001	AB	1	`ea99ee380514…`
2019-07-19 19:46 UTC	2019-07	A075140-002	AB	1	`ea99ee380514…`
2019-07-19 19:46 UTC	2019-07	A075140-003	AB	1	`ea99ee380514…`
2019-07-19 19:46 UTC	2019-07	A075140-004	AB	1	`ea99ee380514…`

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.

DailyMed Billing Units#

Package NDC, Billing unit, Product NDC table
Package NDC	Billing unit	Product NDC	DailyMed indexing SPL	SPL version	Effective
51079-937-01	EA - Each	51079-937	294ee5a6-7732-4c9e-b793-25e317d50649	1	2012-07-24
51079-937-20	EA - Each	51079-937	1346dab4-ddcf-4962-9057-137f4e5c0495	1	2012-07-24

DailyMed Socrata Ingredients#

Ingredient, Type, UNII table
Ingredient	Type	UNII	DailyMed label	SPL version
TERAZOSIN HYDROCHLORIDE ANHYDROUS	ACTIVE INGREDIENT	8QOP8Z9955	TARAZOSIN CAPSULE [MYLAN INSTITUTIONAL INC.]	2
TERAZOSIN	ACTIVE MOIETY	8L5014XET7	TARAZOSIN CAPSULE [MYLAN INSTITUTIONAL INC.]	2
AMMONIA	INACTIVE INGREDIENT	5138Q19F1X	TARAZOSIN CAPSULE [MYLAN INSTITUTIONAL INC.]	2
ANHYDROUS LACTOSE	INACTIVE INGREDIENT	3SY5LH9PMK	TARAZOSIN CAPSULE [MYLAN INSTITUTIONAL INC.]	2
CELLULOSE, MICROCRYSTALLINE	INACTIVE INGREDIENT	OP1R32D61U	TARAZOSIN CAPSULE [MYLAN INSTITUTIONAL INC.]	2
D&C RED NO. 28	INACTIVE INGREDIENT	767IP0Y5NH	TARAZOSIN CAPSULE [MYLAN INSTITUTIONAL INC.]	2
D&C RED NO. 33	INACTIVE INGREDIENT	9DBA0SBB0L	TARAZOSIN CAPSULE [MYLAN INSTITUTIONAL INC.]	2
D&C YELLOW NO. 10	INACTIVE INGREDIENT	35SW5USQ3G	TARAZOSIN CAPSULE [MYLAN INSTITUTIONAL INC.]	2
DIMETHICONE 410	INACTIVE INGREDIENT	TYU5GP6XGE	TARAZOSIN CAPSULE [MYLAN INSTITUTIONAL INC.]	2
FD&C BLUE NO. 1	INACTIVE INGREDIENT	H3R47K3TBD	TARAZOSIN CAPSULE [MYLAN INSTITUTIONAL INC.]	2
FD&C BLUE NO. 2	INACTIVE INGREDIENT	L06K8R7DQK	TARAZOSIN CAPSULE [MYLAN INSTITUTIONAL INC.]	2
FD&C RED NO. 40	INACTIVE INGREDIENT	WZB9127XOA	TARAZOSIN CAPSULE [MYLAN INSTITUTIONAL INC.]	2
FERRIC OXIDE YELLOW	INACTIVE INGREDIENT	EX438O2MRT	TARAZOSIN CAPSULE [MYLAN INSTITUTIONAL INC.]	2
FERROSOFERRIC OXIDE	INACTIVE INGREDIENT	XM0M87F357	TARAZOSIN CAPSULE [MYLAN INSTITUTIONAL INC.]	2
GELATIN	INACTIVE INGREDIENT	2G86QN327L	TARAZOSIN CAPSULE [MYLAN INSTITUTIONAL INC.]	2
MAGNESIUM STEARATE	INACTIVE INGREDIENT	70097M6I30	TARAZOSIN CAPSULE [MYLAN INSTITUTIONAL INC.]	2
PROPYLENE GLYCOL	INACTIVE INGREDIENT	6DC9Q167V3	TARAZOSIN CAPSULE [MYLAN INSTITUTIONAL INC.]	2
SHELLAC	INACTIVE INGREDIENT	46N107B71O	TARAZOSIN CAPSULE [MYLAN INSTITUTIONAL INC.]	2
SILICON DIOXIDE	INACTIVE INGREDIENT	ETJ7Z6XBU4	TARAZOSIN CAPSULE [MYLAN INSTITUTIONAL INC.]	2
SODIUM LAURYL SULFATE	INACTIVE INGREDIENT	368GB5141J	TARAZOSIN CAPSULE [MYLAN INSTITUTIONAL INC.]	2
STARCH, CORN	INACTIVE INGREDIENT	O8232NY3SJ	TARAZOSIN CAPSULE [MYLAN INSTITUTIONAL INC.]	2
TITANIUM DIOXIDE	INACTIVE INGREDIENT	15FIX9V2JP	TARAZOSIN CAPSULE [MYLAN INSTITUTIONAL INC.]	2

UNII, Preferred term, Registry number table
UNII	Preferred term	Registry number	Matched term
8QOP8Z9955	TERAZOSIN HYDROCHLORIDE ANHYDROUS	63074-08-8	TERAZOSIN HYDROCHLORIDE ANHYDROUS

Title, Manufacturer, Effective date table
Title	Manufacturer	Effective date	Type	Version
Terazosin Hydrochloride Anhydrous - Mylan Institutional Inc.	Mylan Institutional Inc.	2019-12-30	HUMAN PRESCRIPTION DRUG LABEL	6